To hear about similar clinical trials, please enter your email below
Trial Title:
68Ga-P3 PET/CT Imaging in Malignancy
NCT ID:
NCT05887687
Condition:
Neoplasms
Conditions: Official terms:
Neoplasms
Conditions: Keywords:
[68Ga]P3
PSMA
PET/CT
Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
[68Ga]P3
Description:
68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Arm group label:
[68Ga]P3
Other name:
[68Ga]-P3
Other name:
PSMA specific PET imaging
Summary:
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that
consists of 750 amino acids. It is highly expressed on most prostate cancer cells and
neovascular endothelial cells of tumors, making PSMA a highly specific and significant
imaging target for malignancies.
[68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in
the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Detailed description:
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that
consists of 750 amino acids. It is highly expressed on most prostate cancer cells and
neovascular endothelial cells of tumors, making PSMA a highly specific and significant
imaging target for malignancies.[68Ga]P3, a novel molecular probe of PET imaging agent
that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA
high-expression malignanciesr.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written
informed consent
Exclusion Criteria:
Pregnant and lactating women; Female patients plan to become pregnant within 6 months.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Peking University First Hospital
Address:
City:
Beijing
Zip:
100034
Country:
China
Status:
Recruiting
Contact:
Last name:
Xing Yang
Phone:
+861083572928
Email:
yangxing2017@bjmu.edu.cn
Start date:
May 20, 2023
Completion date:
July 31, 2025
Lead sponsor:
Agency:
Peking University First Hospital
Agency class:
Other
Source:
Peking University First Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05887687
